Lyra Therapeutics Ownership
| LYRA Stock | USD 11.33 0.01 0.09% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 1.3 M | Current Value 1.3 M | Avarage Shares Outstanding 20.1 M | Quarterly Volatility 19.2 M |
Lyra Stock Ownership Analysis
About 49.0% of the company shares are owned by institutional investors. The book value of Lyra Therapeutics was now reported as 2.94. The company has Price/Earnings To Growth (PEG) ratio of 1.61. Lyra Therapeutics recorded a loss per share of 60.5. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 28th of May 2025. Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Lyra Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 60 people. To find out more about Lyra Therapeutics contact Maria Palasis at 617 393 4600 or learn more at https://lyratherapeutics.com.Besides selling stocks to institutional investors, Lyra Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Lyra Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Lyra Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Lyra Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Lyra Therapeutics Insider Trades History
Less than 1% of Lyra Therapeutics are currently held by insiders. Unlike Lyra Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Lyra Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Lyra Therapeutics' insider trades
Lyra Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lyra Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lyra Therapeutics backward and forwards among themselves. Lyra Therapeutics' institutional investor refers to the entity that pools money to purchase Lyra Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2025-03-31 | 332.6 K | Bnp Paribas Arbitrage, Sa | 2025-03-31 | 242.5 K | Boothbay Fund Management, Llc | 2025-03-31 | 234 K | Susquehanna International Group, Llp | 2025-03-31 | 217.6 K | Two Sigma Investments Llc | 2025-03-31 | 193.1 K | New York State Common Retirement Fund | 2025-03-31 | 154.8 K | Charles Schwab Investment Management Inc | 2025-03-31 | 111.6 K | Rhumbline Advisers | 2025-03-31 | 87.7 K | Bank Of New York Mellon Corp | 2025-03-31 | 71.6 K | Perceptive Advisors Llc | 2025-03-31 | 12.8 M | Blackrock Inc | 2025-03-31 | 3 M |
Lyra Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyra Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyra Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lyra Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyra Therapeutics Outstanding Bonds
Lyra Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Lyra Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Lyra bonds can be classified according to their maturity, which is the date when Lyra Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Lyra Therapeutics Corporate Filings
8K | 9th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 16th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 9th of May 2025 Other Reports | ViewVerify | |
| 4th of April 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (60.50) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets | Return On Equity |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.